Artificial neural network (ANN) velocity better identifies benign prostatic hyperplasia but not prostate cancer compared with PSA velocity

BMC Urology

Volumn 8, Issue 1, 2008, Pages

  Stephan, Carsten ^a   Büker, Nicola ^a   Cammann, Henning ^a   Meyer, Hellmuth Alexander ^a   Lein, Michael ^a,b   Jung, Klaus ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Berlin Institute for Urologic Research   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; ARTIFICIAL NEURAL NETWORK; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISCRIMINANT ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CODING; PROSTATE CANCER; PROSTATE HYPERTROPHY; VELOCITY; ALGORITHM; BLOOD; COHORT ANALYSIS; COMPUTER ASSISTED DIAGNOSIS; DIFFERENTIAL DIAGNOSIS; EVALUATION; MIDDLE AGED; PROSTATE TUMOR; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; COHORT STUDIES; DIAGNOSIS, COMPUTER-ASSISTED; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; MIDDLE AGED; NEURAL NETWORKS (COMPUTER); PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 52249115399     PISSN: 14712490     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-8-10     Document Type: Article

References (33)

1. Prostate specific antigen: a decade of discovery-what we have learned and where we are going. TJ Polascik JE Oesterling AW Partin, J Urol 1999 162 293 306 10.1016/S0022-5347(05)68543-6 10411025
2. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. H Lilja A Christensson U Dahlen MT Matikainen O Nilsson K Pettersson T Lövgren, Clin Chem 1991 37 1618 1625 1716536
3. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. UH Stenman J Leinonen H Alfthan S Rannikko K Tuhkanen O Alfthan, Cancer Res 1991 51 222 226 1703033
4. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. MC Benson IS Whang A Pantuck K Ring SA Kaplan CA Olsson WH Cooner, J Urol 1992 147 815 816 1371554
5. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JE Oesterling SJ Jacobsen CG Chute, JAMA 1993 270 860 866 10.1001/jama.270.7.860 7688054
6. PSA velocity for the diagnosis of early prostate cancer. A new concept. HB Carter JD Pearson, Urol Clin North Am 1993 20 665 670 7505974
7. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. WJ Catalona AW Partin KM Slawin MK Brawer RC Flanigan A Patel JP Richie JB deKernion PC Walsh PT Scardino PH Lange EN Subong RE Parson GH Gasior KG Loveland PC Southwick, JAMA 1998 279 1542 1547 10.1001/jama.279.19.1542 9605898
8. Prostate specific antigen velocity threshold for predicting prostate cancer in young men. S Loeb KA Roehl WJ Catalona RB Nadler, J Urol 2007 177 899 902 10.1016/j.juro.2006.10.028 17296371
9. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. JW Moul L Sun JM Hotaling NJ Fitzsimons TJ Polascik CN Robertson P Dahm MS Anscher V Mouraviev PA Pappas DM Albala, J Urol 2007 177 499 503 10.1016/j.juro.2006.09.063 17222618
10. Usefulness of prostate-specific antigen velocity in screening for prostate cancer. K Ito T Yamamoto M Ohi Y Kubota Y Fukabori K Kurokawa K Suzuki H Yamanaka, Int J Urol 2002 9 316 321 10.1046/j.1442-2042.2002.00466.x 12110095
11. Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer. AP Berger M Deibl A Strasak J Bektic AE Pelzer H Klocker H Steiner G Fritsche G Bartsch W Horninger, Urology 2007 69 134 138 10.1016/j.urology.2006. 09.018 17270635
12. Does PSA velocity predict prostate cancer in pre-screened populations? FH Schroder MJ Roobol TH van der Kwast R Kranse CH Bangma, Eur Urol 2006 49 460 465 10.1016/j.eururo.2005.12.026 16442212
13. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. IM Thompson DP Ankerst C Chi PJ Goodman CM Tangen MS Lucia Z Feng HL Parnes CA Coltman Jr., J Natl Cancer Inst 2006 98 529 534 16622122
14. Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. G Soletormos A Semjonow PE Sibley R Lamerz PH Petersen W Albrecht P Bialk M Gion F Junker HP Schmid H Van Poppel, Clin Chem 2005 51 1342 1351 10.1373/clinchem.2004.046086 15961552
15. The clinical impact of different assays for prostate specific antigen. A Semjonow G De Angelis F Oberpenning HP Schmid B Brandt L Hertle, BJU Int 2000 86 590 597 10.1046/j.1464-410x.2000.00858.x 10971300
16. Discordant performance of assays for free and total prostate-specific antigen in relation to the early detection of prostate cancer. BG Blijenberg G Yurdakul BD Van Zelst CH Bangma MF Wildhagen FH Schroder, BJU Int 2001 88 545 550 10.1046/j.1464-410X.2001.02374.x 11678748
17. Comparison of 6 Automated Assays for Total and Free Prostate-Specific Antigen with Special Reference to Their Reactivity toward the WHO 96/670 Reference Preparation. SA Kort F Martens H Vanpoucke HL van Duijnhoven MA Blankenstein, Clin Chem 2006 52 1568 1574 10.1373/clinchem.2006.069039 16762996
18. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. C Stephan M Klaas C Muller D Schnorr SA Loening K Jung, Clin Chem 2006 52 59 64 10.1373/clinchem.2005.059170 16391327
19. Estimation of prostate cancer probability by logistic regression: free and total prostate-specific antigen, digital rectal examination, and heredity are significant variables. A Virtanen M Gomari R Kranse UH Stenman, Clin Chem 1999 45 987 994 10388474
20. Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network. P Finne R Finne A Auvinen H Juusela J Aro L Maattanen M Hakama S Rannikko TL Tammela U Stenman, Urology 2000 56 418 422 10.1016/S0090-4295(00)00672-5 10962306
21. Analytical performance and clinical validity of two free prostate-specific antigen assays compared. K Jung C Stephan M Lein W Henke D Schnorr B Brux P Schürenkämper SA Loening, Clin Chem 1996 42 1026 1033 8674185
22. Multicenter evaluation of an artificial neural network to increase prostate cancer detection rate and reduce unnecessary biopsies. C Stephan H Cammann A Semjonow EP Diamandis LFA Wymenga M Lein P Sinha SA Loening K Jung, Clin Chem 2002 48 1279 1287 12142385
23. Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network. C Stephan C Xu DA Brown SN Breit A Michael T Nakamura EP Diamandis H Meyer H Cammann K Jung, Prostate 2006 66 651 659 10.1002/pros.20381 16388506
24. A (-5, -7) ProPSA Based Artificial Neural Network to Detect Prostate Cancer. C Stephan HA Meyer M Kwiatkowski F Recker H Cammann SA Loening K Jung M Lein, Eur Urol 2006 50 1014 1020 10.1016/j.eururo.2006.04.011 16697520
25. Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2-10 ng/ml in 4,480 men. C Stephan C Xu H Cammann M Graefen A Haese H Huland A Semjonow EP Diamandis M Remzi B Djavan MF Wildhagen BG Blijenberg P Finne UH Stenman K Jung HA Meyer, World J Urol 2007 25 95 103 10.1007/s00345-006-0132-9 17333205
26. Predictors of prostate cancer evaluated by receiver operating characteristics partial area index: a prospective institutional study. P Gjengsto E Paus OJ Halvorsen J Eide LA Akslen T Wentzel-Larsen PA Hoisaeter, J Urol 2005 173 425 428 10.1097/01.ju.0000149805.83040.1f 15643193
27. Determination of the relative probability for prostate cancer to avoid unnecessary biopsy. K Okamura H Takaba O Kamihira T Kinukawa Y Ono S Ohshima T Nagasaka, Int J Urol 2005 12 346 352 10.1111/j.1442-2042.2005.01056.x 15948720
28. Can PSA patterns be used to identify men with prostate cancer? D Connolly A Black T Nambirajan LJ Murray A Gavin PF Keane, Eur Urol Suppl 2006 5(2) 237 237 10.1016/S1569-9056(06)60865-8
29. Comparison of methods for calculating prostate specific antigen velocity. X Yu M Han S Loeb SN Gashti JT Yeh KA Roehl WJ Catalona, J Urol 2006 176 2427 2431 10.1016/j.juro.2006.08.006 17085120
30. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. R Raaijmakers MF Wildhagen K Ito A Paez SH de Vries MJ Roobol FH Schroder, Urology 2004 63 316 320 10.1016/j.urology.2003.09.028 14972481
31. The association between total prostate specific antigen concentration and prostate specific antigen velocity. X Yu S Loeb KA Roehl M Han WJ Catalona, J Urol 2007 177 1298 1302 10.1016/j.juro.2006.12.003 17382716
32. Is Prostate-Specific Antigen Velocity Useful in Early Detection of Prostate Cancer? A Critical Appraisal of the Evidence. RD Etzioni DP Ankerst NS Weiss LY Inoue IM Thompson, J Natl Cancer Inst 2007 99 1510 1515 10.1093/jnci/djm171 17925534
33. Repeating the measurement of prostate-specific antigen in symptomatic men can avoid unnecessary prostatic biopsy. C Stephan M Lein D Schnorr SA Loening K Jung, BJU Int 2004 93 1360 1361 10.1111/j.1464-410X.2004.4886e.x 15180645